Gilead Signs an Agreement with Carna Biosciences to Develop and Commercialize Immuno-Oncology Therapies

Shots:

• Carna to receive $20M upfront, up to $450M as development & commercial milestones and royalties on sales. Gilead to get WW rights to develop and commercialize inhibitors against immuno-oncology target and an exclusive right to access Carna’s lipid kinase drug discovery platform
• The focus of the collaboration is to advance novel immunotherapies targeting cancer by utilizing Carna’s lipid kinase drug discovery platform
• Carna Biosciences focuses on developing kinase inhibitors targeting oncology, autoimmune and neurological diseases by inhibiting kinases which are important drivers for the diseases

Click here to read full press release/ article | Ref: Gilead | Image: Atelier Ten